Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
There’s a new collaboration in the Parkinson’s disease development space, Cardiff Oncology kicks off a mid-phase study in colorectal cancer and Ocugen published a new review of COVAXIN.
Two days after unveiling an executive order to boost U.S. biomanufacturing, the White House unveiled plans that include $2 billion to support the initiative.
After reporting a failed clinical trial of ELX-02 for cystic fibrosis (CF), Eloxx Pharmaceuticals plans to shift its focus and use the drug to treat Alport syndrome, a rare kidney disease.
Researchers at PrecisionLife say they have found a genetic link to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Novartis confirmed it is the subject of an investigation by the Swiss Competition Commission over possible unlawful patent use.
Pfizer is leveraging its funding and experience with vaccines, developing its meningococcal, flu, and RSV vaccines. It also announced its venture investment in Nimbus Therapeutics.
Gala Therapeutics and Galaxy Medical will be folded into Galvanize Therapeutics to continue to develop their electric pulse therapies for bronchitis, cardiac arrhythmias and solid tumors.
The Institute for Clinical and Economic Review (ICER) concluded that even at a hefty lifetime cost of $2.5 million, gene therapies for hemophilia A and B are worth it.
NSCLC At ESMO: Pollution does indeed cause lung cancer; Tecentriq shows promise in poor prognosis patients, Amgen makes progress in KRAS G12-mutated disease and an update on a Daiichi Sankyo ADC.
Biden issued an executive order to keep U.S.-based innovation ahead of advances made by counterparts in China biotechnology and biomanufacturing Monday.
The growing geriatric population and rapid advancements in medical imaging technologies are other factors that could favor orthopedic medical imaging equipment market growth across the forecast period.
This week was rife with Series financings, which channeled money into innovative treatments for immune diseases and cancers, genomic treatments and precision healthcare.
PRESS RELEASES
Head-to-Head Study Highlights Rocbrutinib as the World’s First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations
Corporate Treasury Positioned with Cash and Liquid Equity Holdings to Seed, Incubate and Accelerate New and Existing Operations